Work

Long-Acting Injectable HIV Therapy Outcomes Among Persons With HIV Who Have Adherence Challenges to Oral Antiretroviral Therapy

Year: 2025

Type: article

Abstract: Long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) may improve outcomes among persons with human immunodeficiency virus (PWH) with adherence difficulties to oral therapy. In this real-world observational study, over 85% of PWH remained on therapy and virally suppressed 48 weeks after initiating LAI-CAB/RPV. Providers should consider LAI therapy among PWH with adherence difficulties.

Source: Clinical Infectious Diseases

DOI: 10.1093/cid/ciaf120

Authors: Elizabeth Hastie, Lucas Hill, Laura Bamford, Afsana Karim, Thomas C S Martin

Institutions: University of California San Diego, VA San Diego Healthcare System

Language: English

Topic: HIV/AIDS Research and Interventions

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,763